Dipeptidyl peptidase-4 (DPP-4) inhibitors have gained extensive importance as effective antidiabetic drugs in the management of type 2 diabetes mellitus (T2DM). Linagliptin, the most recent additions to incretin-based therapies have demonstrated adequate efficacy, a favorable safety profile, especially cardiovascular and renal safety. This has highlighted additional interest in the potential use of Linagliptin in the management of T2DM. 1 In this regard, Boehringer Ingelheim India and Docplexus have organized an interactive webinar on 6th October 2020 from 08:00 PM to 09.00 PM IST.
In this webinar, Dr. Stefano Del Prato will share his insights on t he lessons from a decade of Linagliptin for the impending diabetes therapy optimization. Reference: Gallwitz B, Frontiers in endocrinology. 2019;10.
